- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06189040
Immunogenicity After COVID-19 Vaccines in Adapted Schedules (IMCOVAS)
Assessment of the Immunogenicity and Safety of Marketed Vaccines for COVID-19 After Regular Schedule and Adapted Vaccine Schedules and Routes: BNT162b2, mRNA-1273 Vaccine and ChAdOx1-S [Recombinant]
The goal of this clinical trial is to compare different Coronavirus Disease 2019 (COVID-19) vaccination schedules in healthy adults that have not yet been exposed to SARS-CoV-2, the virus causing COVID-19. The main questions it aims to answer are:
- Is it possible to adapt COVID-19 vaccination schedules while maintaining an adequate humoral immune response?
- Is it possible to adapt COVID-19 vaccination schedules while maintaining an acceptable safety profile?
Participants will be vaccinated twice with a COVID-19 vaccine (on day 0, and on day 28 or 84). After each vaccination, they will collect information about adverse events in a diary for 14 days. Information about the occurrence of events such as hospitalizations and infections with SARS-CoV-2 will be collected by the investigator for up to 364 days after the first vaccination. Blood samples will be taken on different timepoints and used to assess immunity against SARS-CoV-2.
Researchers will compare 8 vaccination schedules to see if the immune response and safety profile is similar. Each participant will receive 1 of the following 8 vaccine schedules:
- BNT162b2 (30µg) on day 0, followed by BNT162b2 (30µg) on day 28
- BNT162b2 (20µg) on day 0, followed by BNT162b2 (20µg) on day 28
- BNT162b2 (30µg) on day 0, followed by BNT162b2 (30µg) on day 84
- BNT162b2 (30µg) on day 0, followed by mRNA-1273 (100µg) on day 28
- BNT162b2 (30µg) on day 0, followed by ChAdOx1-S [recombinant] on day 28
- BNT162b2 (6µg, intradermal administration) on day 0, followed by BNT162b2 (6µg, intradermal administration) on day 28
- mRNA-1273 (100µg) on day 0, followed by mRNA-1273 (100µg) on day 28
- mRNA-1273 (50µg) on day 0, followed by mRNA-1273 (50µg) on day 28
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Antwerp, Belgium, 2000
- Institute of Tropical Medicine (ITM)
-
Brussels, Belgium, 1070
- Hôpital Erasme
-
-
Antwerp
-
Edegem, Antwerp, Belgium, 2650
- Centre for the Evaluation of Vaccination (CEV)
-
-
East Flanders
-
Ghent, East Flanders, Belgium, 9000
- Centre for Vaccinology (CEVAC)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male, female, or X (non-binary gender) subjects, 18-55y inclusive on the day of signing of the ICF
- Provision of signed and dated informed consent form
- Available at all provided timepoints of the study and is not planning to move abroad for the whole duration of the study
- In good general health as evidenced by medical history and/or physical examination or adults with pre-existing medical conditions who are in stable condition. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months before enrollment.
- Willing and able to comply with all study procedures
Participants born female must be either:
- of childbearing potential and using effective contraception for at least 1 month prior to screening and agree to use such a method during study participation until 1 months following the last study dose administration.
- of non-childbearing potential.
Exclusion Criteria:
- Previous clinical or microbiological confirmed diagnosis of COVID-19.
- Febrile illness within 72hours before first vaccination (this is a temporary exclusion criterion).
- Unstable, severe, progressive disease in the past 3 months.
- History of malignancy during the past 5 years.
- History of severe adverse reaction associated and/or anaphylaxis with a vaccine.
- Known allergic reactions of any severity to polyethylene glycol [PEG] or to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG).
- Primary or secondary immunodeficiency disorders (e.g. immunosuppressive disease or therapy, human immunodeficiency virus (HIV) infection…).
- Chronic administration (defined as more than 14 days in total) of immunosuppressant or other immune-modifying drugs during the period starting 6 months prior to the first vaccine dose. For corticosteroids, this will mean prednisone 20 mg/day, or equivalent. Inhaled, nasal, opthalmic and topical steroids are allowed.
- Pregnancy or lactation.
- History of drug or alcohol abuse.
- Anything in the opinion of the investigator that would prevent volunteers from completing the study or put the volunteer at risk, including relevant psychiatric diagnosis.
- Previous vaccination or planned to accept other vaccination during this study with any coronavirus vaccine outside this study.
- Previous vaccination or planned to accept other vaccination during this study with any coronavirus vaccine outside this study, with the exception of a third COVID-19 vaccine during fall/winter '21-'22.
- Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
- Participation in another clinical trial with an IMP or a new medical device within 28 days prior to study entry and/or during study participation.
- Participant is an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as first degree family members and household members of the employees or the investigator, or an employee of the sponsor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BNT162b2 regular schedule
day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of BNT162b2 (30µg)
|
intramuscular administration of 30µg
|
Experimental: BNT162b2 + mRNA-1273 schedule
day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of mRNA-1273 (100µg)
|
intramuscular administration of 30µg
intramuscular administration of 100µg
|
Experimental: BNT162b2 + ChAdOx1-S schedule
day 0: intramuscular administration of BNT162b2 (30µg) day 28: intramuscular administration of ChAdOx1-S [recombinant] (not less than 2.5x10^8 infectious units)
|
intramuscular administration of 30µg
intramuscular administration of not less than 2.5 x 10^8 infectious units
|
Experimental: BNT162b2 low dose schedule
day 0: intramuscular administration of BNT162b2 (20µg) day 28: intramuscular administration of BNT162b2 (20µg)
|
intramuscular administration of 20µg
|
Experimental: BNT162b2 long-interval schedule
day 0: intramuscular administration of BNT162b2 (30µg) day 84: intramuscular administration of BNT162b2 (30µg)
|
intramuscular administration of 30µg
|
Experimental: BNT162b2 intradermal schedule
day 0: intradermal administration of BNT162b2 (6µg) day 28: intradermal administration of BNT162b2 (6µg)
|
intradermal administration of 6µg
|
Active Comparator: mRNA-1273 regular schedule
day 0: intramuscular administration of mRNA-1273 (100µg) day 28: intramuscular administration of mRNA-1273 (100µg)
|
intramuscular administration of 100µg
|
Experimental: mRNA-1273 low dose schedule
day 0: intramuscular administration of mRNA-1273 (50µg) day 28: intramuscular administration of mRNA-1273 (50µg)
|
intramuscular administration of 50µg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric mean titre of antibodies binding to the Receptor Binding Domain of SARS-CoV-2 S protein of the ancestral D614 SARS-CoV-2 virus strain
Time Frame: 28 days after the administration of the second study vaccine
|
28 days after the administration of the second study vaccine
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of solicited adverse events
Time Frame: within 5 days after the administration of each study vaccine
|
within 5 days after the administration of each study vaccine
|
Occurrence of unsolicited adverse events
Time Frame: within 14 days after the administration of each study vaccine
|
within 14 days after the administration of each study vaccine
|
Occurrence of medically attended adverse events, adverse of special interest and serious adverse events
Time Frame: through study completion (up to 1 year after the first study vaccination)
|
through study completion (up to 1 year after the first study vaccination)
|
Occurrence of absenteeism
Time Frame: within 5 days after the administration of each study vaccine
|
within 5 days after the administration of each study vaccine
|
Geometric mean titre of antibodies binding to the Receptor Binding Domain of SARS-CoV-2 S protein of the ancestral D614 SARS-CoV-2 virus strain
Time Frame: 28 days after the administration of the third COVID-19 vaccine
|
28 days after the administration of the third COVID-19 vaccine
|
Geometric mean titre of neutralizing antibodies to the ancestral D614 SARS-CoV-2 virus strain and variants of concern
Time Frame: 28 days after the administration of the second study vaccin
|
28 days after the administration of the second study vaccin
|
Geometric mean titre of neutralizing antibodies to the ancestral D614 SARS-CoV-2 virus strain and variants of concern
Time Frame: 28 days after the administration of the third COVID-19 vaccine
|
28 days after the administration of the third COVID-19 vaccine
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PCR-confirmed SARS-CoV-2 infection with COVID-19 symptoms (any severity)
Time Frame: through study completion (up to 1 year after the first study vaccination)
|
through study completion (up to 1 year after the first study vaccination)
|
PCR-confirmed SARS-CoV-2 infection with severe COVID-19 (hospitalization, death)
Time Frame: through study completion (up to 1 year after the first study vaccination)
|
through study completion (up to 1 year after the first study vaccination)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Katie Steenackers, MD, Centre for the Evaluation of Vaccination
- Principal Investigator: Nikita Hanning, MD, Centre for the Evaluation of Vaccination
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMCOVAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
Clinical Trials on BNT162b2 30µg
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
BioNTech SEPfizerCompletedCOVID-19 | SARS-CoV-2 InfectionUnited States, Brazil, South Africa, Germany, Canada, Israel
-
BioNTech SEPfizerCompleted
-
BioNTech SEPfizerCompletedSARS-CoV-2 Infection, COVID-19United States, Spain, Finland, Poland, Mexico, Brazil
-
PfizerCompleted
-
The University of Hong KongRecruitingImmunocompromised Patients | Intradermal Covid-19 Vaccine | Immungenicity and Safety | Randomized TrialHong Kong
-
Murdoch Childrens Research InstituteCoalition for Epidemic Preparedness Innovations; The Peter Doherty Institute...Withdrawn
-
BioNTech SEPfizerCompletedSARS-CoV-2 Infection, COVID19United States, Brazil, Germany, Mexico
-
BioNTech SEPfizerRecruitingCOVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | SARS-CoV-2 VirusUnited States, South Africa, Brazil, Puerto Rico
-
BioNTech SEPfizerCompletedCOVID-19 | SARS-CoV-2 InfectionUnited States